Exosomes in cancer metastasis: Novel targets for diagnosis and therapy?

Cancer Forum

Volumn 38, Issue 2, 2014, Pages 116-120

  Wen, Shu Wen ^a   Lobb, Richard ^a   Möller, Andreas ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905818507     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012; 1820:940-948.
2. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol. 2002; 168:3235-3241. (Pubitemid 34250383)
3. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161-1172. (Pubitemid 26113979)
4. Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C et al. Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell. 1997; 8:2631-2645. (Pubitemid 27528227)
5. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7:297-303. (Pubitemid 32224344)
6. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006; 107:102-108. (Pubitemid 44779821)
7. Martins VR, Dias MS, Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol. 2013; 25:66-75.
8. Szajnik M, Derbis M, Lach M, Patalas P, Michalak M et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol Obstet (Sunnyvale). 2013; Suppl 4: 3.
9. Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW et al. Survivin is released from cancer cells via exosomes. Apoptosis. 2011; 16:1-12.
10. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 4: e5219.
11. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2013; 12:421.
12. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009; 284:34211-34222.
13. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9:239-252.
14. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013; 110:7312-7317.
15. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009; 124:2621-2633.
16. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009; 106:3794-3799.
17. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May Let al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10:619-624. (Pubitemid 351627382)
18. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012; 227:658-667.
19. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med. 2012; 18:883-891.
20. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012; 119:756-766.
21. Stoorvogel W. Functional transfer of microRNA by exosomes. Blood. 2012; 119:646-648.
22. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9:654-659. (Pubitemid 47214727)
23. Aliotta JM, Pereira M, Li M, Amaral A, Sorokina Aet al. Stable cell fate changes in marrow cells induced by lung-derived microvesicles. J Extracell Vesicles. 2012; 1.
24. Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics. 2013; 12:343-355.
25. Kieran MW, Folkman J, Heymach J. Angiogenesis inhibitors and hypoxia. Nat Med. 2003; 9:1104; author reply 1104-1105.
26. Pang RW, Poon RT. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag. 2006; 2:97-108. (Pubitemid 43853426)
27. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991; 324:1-8.
28. Hood JL, Pan H, Lanza GM, Wickline SA, Consortium for Translational Research in Advanced I et al. Paracrine induction of endothelium by tumor exosomes. Lab Invest. 2009; 89:1317-1328.
29. Park JE, Tan HS, Datta A, Lai RC, Zhang H et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010; 9:1085-1099.
30. van Balkom BW, de Jong OG, Smits M, Brummelman J, den Ouden K et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood. 2013; 121:3997-4006, S3991-3915.
31. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006; 66:9290-9298. (Pubitemid 44521151)
32. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12:253-268.
33. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005; 11:1010-1020. (Pubitemid 40175748)
34. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res; 2003; 9:5113-5119. (Pubitemid 37413559)
35. Liu C, Yu S, Zinn K, Wang J, Zhang L et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006; 176:1375-1385. (Pubitemid 43134279)
36. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012; 7:e50999.
37. Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer. 2009; 125:1595-1603.
38. Lv LH, Wan YL, Lin Y, Zhang W, Yang M et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem. 2012; 287:15874-15885.
39. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005; 4:1595-1604. (Pubitemid 41556443)
40. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006; 127:679-695. (Pubitemid 44781029)
41. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3:453-458. (Pubitemid 37328849)
42. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009; 9:285-293.
43. Sceneay J, Parker BS, Smyth MJ, Moller A. Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. Oncoimmunology. 2013; 2:e22355.
44. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013; 32(3-4):449-64
45. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011; 71:5346-5356.
46. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151:1542-1556.
47. Luga V, Wrana JL. Tumor-stroma interaction: Revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res 2013 73: 6843-6847.
48. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010; 70:1668-1678.
49. Cai Z, Yang F, Yu L, Yu Z, Jiang L et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol. 2012; 188:5954-5961.
50. Lee YS, Kim SH, Cho JA, Kim CW. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp Mol Med. 2011; 43:281-290.
51. Escudier B, Dorval T, Chaput N, Andre F, Caby MP et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005; 3:10.
52. Morse MA, Garst J, Osada T, Khan S, Hobeika A et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3:9.
53. Viaud S, Thery C, Ploix S, Tursz T, Lapierre V et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res. 2010; 70:1281-1285.
54. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010; 120:457-471.
55. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319:1244-1247. (Pubitemid 351323020)
56. Fabbri M, Paone A, Calore F, Galli R, Gaudio E et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012; 109:E2110-2116.
57. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012; 10:134.